Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma
Lenvatinib is the first-line treatment for hepatocellular carcinoma (HCC), the most common type of primary liver cancer; however, some patients become refractory to lenvatinib. The underlying mechanism of lenvatinib resistance (LR) in patients with advanced HCC remains unclear. We focused on explori...
Main Authors: | Dawei Sun, Juan Liu, Yunfang Wang, Jiahong Dong |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.944537/full |
Similar Items
-
Magnolol and Honokiol Inhibited the Function and Expression of BCRP with Mechanism Exploration
by: Chung-Ping Yu, et al.
Published: (2021-12-01) -
The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer
by: Lei Zhang, et al.
Published: (2020-01-01) -
Safety and efficacy of radiotherapy combined with lenvatinib plus PD-1 inhibitors as neo-adjuvant therapy in hepatocellular carcinoma with portal vein thrombus: protocol of an open-label, single-arm, prospective, multi-center phase I trial
by: Guangxin Li, et al.
Published: (2022-11-01) -
Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma
by: Katsuki Miyazaki, et al.
Published: (2023-02-01) -
Characterization of a Potent, Selective, and Safe Inhibitor, Ac15(Az8)<sub>2</sub>, in Reversing Multidrug Resistance Mediated by Breast Cancer Resistance Protein (BCRP/ABCG2)
by: Tsz Cheung Chong, et al.
Published: (2022-10-01)